Description
Indication & Scope
MeiYouHeng® is a prescription EGFR-targeted antibody-drug conjugate (ADC) indicated for the treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma who have previously failed at least two lines of systemic chemotherapy and PD-1/PD-L1 inhibitor therapy.
- Mechanism: Becotatug vedotin is an EGFR-directed antibody-drug conjugate composed of a humanized anti-EGFR monoclonal antibody, a protease-cleavable valine-citrulline linker, and the microtubule inhibitor monomethyl auristatin E (MMAE). After binding to EGFR-expressing tumor cells, the ADC is internalized and releases MMAE intracellularly, inducing apoptosis and exerting a bystander antitumor effect.
- Drug class: EGFR-targeted antibody-drug conjugate (ADC).
- Clinical use: Treatment of recurrent or metastatic nasopharyngeal carcinoma following failure of chemotherapy and PD-1/PD-L1 inhibitors.
| Generic Name | Becotatug Vedotin for Injection |
| Brand Name | MeiYouHeng® |
| Ingredient | Becotatug vedotin |
| Dosage Form | Lyophilized powder for injection |
| Package | 50 mg/bottle |
| Conditions Treated | Recurrent/metastatic nasopharyngeal carcinoma |
| Taboos | Hypersensitivity to becotatug vedotin, MMAE, or any component of the product; pregnancy |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store refrigerated at 2–8°C and protect from light. Do not freeze. |
| Manufacturer | Lepu Biopharma Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20250057 |
| Date of Revision | 2025 |
| Shelf Life | Refer to the approved package labeling. |
How to use ?
Recommended Dose: The recommended dose is 2.3 mg/kg administered by intravenous infusion once every 3 weeks (Q3W) until disease progression, unacceptable toxicity, or treatment discontinuation.
Time: Administer by intravenous infusion according to the approved prescribing information. Routine premedication is generally not required.
Instructions for use: Becotatug vedotin should be administered under the supervision of healthcare professionals experienced in antineoplastic therapy. Patients should be monitored regularly for hematologic toxicity, peripheral neuropathy, and signs of infection throughout treatment. Dose interruption, reduction, or discontinuation may be required based on adverse reactions.
Interaction: No formal drug interaction studies have been conducted. Becotatug vedotin primarily exerts its activity through intracellular release of MMAE after tumor cell internalization and has no known clinically significant interactions with chemotherapy, targeted therapy, or immune checkpoint inhibitors.
Side effects: Common adverse reactions include neutropenia, leukopenia, anemia, lymphopenia, hyponatremia, hypokalemia, rash, fatigue, peripheral neuropathy, and intestinal obstruction. Most adverse events are manageable with appropriate supportive care and dose modification.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What type of drug is Becotatug vedotin?
It is an EGFR-targeted antibody-drug conjugate (ADC).
How does Becotatug vedotin work?
It selectively binds EGFR-positive tumor cells and delivers the cytotoxic payload MMAE to induce tumor cell death.
How is the drug administered?
It is administered by intravenous infusion once every three weeks.
What are the most common adverse reactions?
The most common adverse reactions include hematologic toxicities, peripheral neuropathy, rash, fatigue, and electrolyte abnormalities.
MeiYouHeng® | Becotatug Vedotin | Recurrent/Metastatic Nasopharyngeal Carcinoma | DengYueRX
INN: Becotatug vedotin
Indications: Recurrent/metastatic nasopharyngeal carcinoma
Dosage Form: Lyophilized powder for injection
Strength: 50 mg/Bottle
